Nosocomial Infection Treatment Market will be Growing at a CAGR of 2.5 % during the forecast period from 2016 to 2024

The latest market report published by Acute Market Reports, Inc., the global market for nosocomial infection treatment was valued at US$ 28,565 million in 2015 and is expected to reach US$ 36,746 million by 2024, increasing to CAGR by 2.5 per cent from 2016 to 2024.

Market Insights

Nosocomial infection, also known as Acquired or Associated Hospital Infection (HAI), is defined as an infection developed in patients who have not previously been present or incubated during hospital admission. Nosocomial infection is mainly caused by bacteria, viruses or fungal pathogens and is becoming the world’s leading cause of morbidity and mortality, causing enormous economic burdens. The market for the treatment of nosocomial infections is expected to increase throughout the forecast period. Major factors contributing to the growth of the HAI market are increasing prevalence of nosocomial infections, increasing government initiatives and increasing public awareness of quality hygiene in hospitals, increasing geriatric population immunocompromised patients, advances in air handling units and other cleaning technologies. Multidrug resistance is observed in patients mainly due to excessive use of antibiotics, which is one of the causes of increased prevalence of nosocomial infection. The regulatory authorities have established guidelines for hospitals and clinics and instructed them to comply with these guidelines for the prevention of nosocomial infections and to adopt best health practices along with a strategy for the control of infections.

Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/nosocomial-infection-treatment-market

The global market for nosocomial infections is segmented by type of infection such as pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA, etc. Pneumonia, urinary tract infection (UTI), surgical site infection (SSI) and MRSA are the major types of hospital-acquired infections with the highest prevalence.

Nosocomial infection treatment market is segmented on the basis of treatment type as antibacterial, antifungal, antiviral treatment and others. Antibacterial treatment accounted for the largest market share in 2015. As of the current market scenario, North America is the largest regional market for nosocomial infection treatment, followed by Europe and Asia Pacific. North America dominates the global nosocomial infection treatment market attributed to rise in prevalence of nosocomial infections, mounting cases of multi-drug resistant microbial infections and rising demand for advanced therapeutics. Asia Pacific is anticipated to be the fastest growing market during the forecast period. The key factors responsible for its significant growth are emerging economies with developing healthcare market due to pouring investments in healthcare infrastructure by public and private sector, increase in prevalence of nosocomial infection, and high health awareness coupled with growing disposable income.

Market Competition Assessment:

Key players in the nosocomial infection treatment market are

Abbott Vascular Inc., Bayer, Becton, Dickinson and Company, Belimed, BioMerieux, Cantel, Cepheid, Getinge Group, Kimberly-Clark Corp., Merck & Co, Nordion, Pfizer, Roche, Sakura Seiki, BioMérieux, Steris, Johnson & Johnson, Sterigenics International, Inc., Halyard Health, Inc., Advanced Sterilization Products, Matachana Group etc.

Key Market Movements:

• Rise in prevalence of nosocomial infection due to an increase in patient pool  of chronic diseases, growth in geriatric population which are more prone to infection
• With increase in number of surgical procedures with medical advancement is potential risk for the patient due to infection caused by the surgical equipment’s or by healthcare workers; patient compromise with immunity are more vulnerable to infection
• In emerging economies, the rise in number of hospital increases the chances of nosocomial infection thus leading to growth of hospital infection prevention and control market

Report Scope by Segments

By Infection Type

• Ventilator Associated Pneumonia
• Urinary Tract Infection
• Blood Stream Infection
• Surgical Site Infection
• Gastrointestinal Infection
• MRSA
• Others (ENT Infections, Skin Infection, and Bone Infection)

By Treatment Type

• Antibacterial Treatment
• Antiviral Treatment
• Antifungal Treatment
• Others

By Geography Segment

 • North America (U.S., Rest of North America)

 • Europe (U.K., Germany, France, Rest of Europe)

 • Asia Pacific (China, Japan, India,Rest of Asia Pacific)

 • Rest of the World (Middle East & Africa, Latin America)